Table 2
Parameter: RNA loading | Reported procedure / limitation: AMG1541:mRNA 10:1 by mass; reported N/P 11.4:1. | Source: SI Table 1
sales@dcchemicals.com
AMG1541
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 2
Parameter: Lipid stocks | Reported procedure / limitation: AMG lipid 40 mg/mL in ethanol; helper lipid stocks 10 mg/mL in ethanol. | Source: Main Methods
Table 2
Parameter: Aqueous phase | Reported procedure / limitation: mRNA 133 ng/µL in 10 mM citrate, pH 3.0. | Source: Main Methods
Table 2
Parameter: Microfluidics | Reported procedure / limitation: Herringbone channel; aqueous:ethanol 3:1; total flow 1.2 mL/min. | Source: Main Methods
Table 2
Parameter: Comparator context | Reported procedure / limitation: SM-102 uses DSPC with a 50:10:38.5:1.5 recipe. Lipid chemistry and helper composition therefore both differ in the principal comparison. | Source: SI Table 1
Table 3
Measurement / batch: Representative AMG1541 batch | Reported result: Diameter 85 nm; PDI 0.107; encapsulation 67% | Evidence context: SI Table 3; no replicate dispersion supplied in that table
Table 3
Measurement / batch: Apparent particle pKa | Reported result: Approximately 6.5, TNS assay | Evidence context: Main / SI characterization
Table 3
Measurement / batch: RNA protection / storage | Reported result: Evaluate the particular RNA-loaded formulation and conditions | Evidence context: Not a release specification for neat lipid
Table 4
Experiment and dose: IM reporter expression BALB/cJ mice; Fluc mRNA 1 µg IM | Readout and comparator: Readout: 6 h Comparator: SM-102 and cKK-E12 study LNPs | Result and source: Reported expression 3.5-fold above SM-102 and 1.7-fold above cKK-E12. Figure caption states n=3–6; archived source-data entry count requires reconciliation. Fig. 2c; mean ± SD; study ANOVA
Table 4
Experiment and dose: Off-site liver expression IM Fluc mRNA 1 µg | Readout and comparator: Readout: 6 h Comparator: SM-102 study LNP | Result and source: Reported liver expression 8.3-fold lower than SM-102, despite higher injection-site expression. This measures expression, not total particle accumulation. Fig. 2f; comparator-specific n in caption
Table 4
Experiment and dose: Influenza-antigen dose response HA H3 Tasmania/2020 mRNA; female BALB/cJ mice; 0.01, 0.1 or 1 µg; prime day 0, boost day 21 | Readout and comparator: Readout: Serum day 35 Comparator: SM-102 LNP | Result and source: The 0.01 µg AMG1541 arm produced antibody/HAI responses comparable to the 1 µg SM-102 arm under the reported assay. This is not a virus-challenge protection experiment. Vaccine figures; n=5
Table 4
Experiment and dose: Sex and strain comparison HA immunization in male/female BALB/c and female C57BL/6 mice | Readout and comparator: Readout: Day 35 Comparator: Corresponding SM-102 arms | Result and source: Reported binding-antibody improvements were 15.8-fold, 6.8-fold and 5.8-fold, respectively. These are separate groups rather than one universal fold change. Main vaccine results; n=5 per group
Table 4
Experiment and dose: Post-boost cytokines HA vaccine study; serum cytokine panel | Readout and comparator: Readout: 6 h after boost Comparator: SM-102 arms | Result and source: Most measured cytokines were comparable; female IL-2 was approximately fivefold higher. The data do not support a blanket “no inflammation” statement. Main cytokine results
Table 4
Experiment and dose: PK identity limitation Muscle lipid measurements in source-data files | Readout and comparator: Readout: Time-course study Comparator: Related AMG lipids | Result and source: A source-data label identifies AMG1041 in a context discussed alongside AMG1541. Quantitative AMG1541 clearance values are not assigned from that unresolved table. Fig. 2e source-data label / SI PK methods